This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Gavreto (pralsetinib)
General Description:
Gavreto (pralsetinib) is a targeted therapy approved for treating adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), as well as those with advanced or metastatic thyroid cancer.
GettingGavreto (pralsetinib)in India
Gavreto (pralsetinib) has been approved in countries like the U.S. and Europe but is not yet available for commercial sale in India. However, it is accessible through the Named Patient Program (NPP) for eligible patients.
MitoGENE helps Indian patients accessGavreto (pralsetinib)legally and safely under their doctor’s supervision. We handle the documentation, regulatory approvals, and logistics to ensure compliance with Indian regulations.
If you or your loved one may benefit from Gavreto (pralsetinib), MitoGENE is here to support your journey to access this treatment.
Disease Indications: Lung Cancer, Thyroid Cancer
Manufacturer: Roche
Usage: Oral
Medicine Approved by:
- European Medical Agency (EMA)
- Food and Drug Administration (FDA)
Available Dosage Form& Package
- 120 capsules of 100 mg
Shipping:Room Temperature Shipping. This medication is shipped using standard delivery methods, ensuring it remains within a controlled room temperature range of 15°C to 25°C throughout transit.
How to Access Gavreto (pralsetinib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Gavreto (pralsetinib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
